Bifogade filer
PDF
Kurs
-5,93%
Likviditet
0,02 MSEK
Kalender
| Est. tid* | ||
| 2026-03-03 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-04 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-12 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-14 | N/A | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2025-05-13 | N/A | Årsstämma |
| 2025-05-06 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-03-04 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-13 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-05 | - | Bokslutskommuniké 2023 |
| 2023-10-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-15 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-17 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-03-07 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-16 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-03 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-08 | - | Bokslutskommuniké 2021 |
| 2021-11-02 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2021-05-24 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-08 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2020-05-19 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-19 | - | Extra Bolagsstämma 2019 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Extra Bolagsstämma 2018 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-01 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2018-02-28 | - | Årsstämma |
| 2018-01-30 | - | Bokslutskommuniké 2017 |
| 2017-05-31 | - | Extra Bolagsstämma 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Scandinavian ChemoTech AB (publ) hereby publishes the Year-End Report for 2024.
Fourth-quarter sales reached 2 041 KSEK, which is the best quarter in 2024. Total annual sales amounted to 6 566 KSEK-entirely from Animal Care. If reported separately, Animal Care would show a positive result in 2024. According to our calculations the operating profit would be approximately 475 KSEK.
The report is attached to this press release and can also be downloaded from the company's website.
(https://www.chemotech.se/investor-relations/financial-reports/)
Fourth quarter 2024
-
Net sales amounted to 2 041 KSEK (507)
-
Profit/loss after financial items amounted to -3 167 KSEK (-5 148)
-
Earnings per share amounted to -0,14 SEK (-0,35)
-
Cash flow from operating activities amounted to -2 172 KSEK (-3 396)
Full year 2024
-
Net sales amounted to 6 566 KSEK (2 822)
-
Profit/loss after financial items amounted to -13 717 KSEK (-21 091)
-
Earnings per share amounted to -0,66 SEK (-1,56)
-
Cash flow from operating activities amounted to -13 145 KSEK (-18 227)
-
All orders were delivered at the end of the period
Events during the reporting period
-
ChemoTech's Animal Care enters strategic collaboration with Norwegian Veterinary University's Hospital for Equine Medicine
-
Animal Care is heading towards a strong fourth quarter of 2024 in terms of sales.
-
ChemoTech splits business units to boost cash flow and will suggest a new name for the Group
Events after the reporting period
-
ChemoTech implements management changes to reduce costs and boost revenue
-
ChemoTech's Animal Care operations showed positive cashflow for 2024 in separate reporting
-
ChemoTech restructures loans and doubles the duration to 12 months
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-03-2025 08:30 CET.